Home > Inhibitors & Agonists > Epigenetics > Bromodomain
Cat. No. Product name CAS No.
DC10656 (+)-JQ1 carboxylic acid

(+)-JQ1 carboxylic acid is the carboxylic acid form of (+)-JQ1 for derivative synthesis.

202592-23-2
DC5019 (+)-JQ1

(+)-JQ1 is a BET bromodomain inhibitor, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

1268524-70-4
DC12021 (+)-JQ1 PA

(+)-JQ1 PA is a Click-activated (alkyne) version of the BET bromodomain inhibitor (+)-JQ1.

2115701-93-2
DC11652 Ischemin sodium

A cell permeable CBP bromodomain inhibitor with Kd of 19 uM.

DC11653 Ischemin

A cell permeable CBP bromodomain inhibitor with Kd of 19 uM.

1357059-00-7
DC7565 BET bromodomain inhibitor,cas 1505453-59-7

A new compound which is similar with +JQ-1,BET bromodomain inhibitor

1505453-59-7
DC11793 UMB-32

A novel a potent, selective inhibitor of BRD4 with Kd of 550 nM, cellular IC50 of 724 nM.

1635437-39-6
DC11792 UMB-136

A novel bromodomain BRD4 inhibitor that significantly induces HIV-1 reactivation.

2109805-83-4
DC11730 GNE-207

A novel potent, selective, orally active CBP/p300 bromodomain with IC50 of 1.0 nM.

2158266-58-9
DC11568 HJB-97

A potent BET bromodomian inhibitor with IC50 of 3-7 nM for BRD2/3/4 BD1 and BD2..

2093391-24-1
DC11452 ABBV-744

ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastic castration-resistant prostate cancer.BBV-744, a highly potent and selective inhibitor of the BD2 domain of BET family proteins with drug-like properties. In contrast to the broad range of cell growth inhibition induced by DbBi, the antiproliferative activity of ABBV-744 was largely, but not exclusively, restricted to cell lines of acute myeloid leukaemia and prostate cancer that expressed the full-length androgen receptor (AR). ABBV-744 retained robust activity in prostate cancer xenografts, and showed fewer platelet and gastrointestinal toxicities than the DbBi ABBV-07514.Analyses of RNA expression and chromatin immunoprecipitation followed by sequencing revealed that ABBV-744 displaced BRD4 from AR-containing super-enhancers and inhibited AR-dependent transcription, with less impact on global transcription compared with ABBV-075. These results underscore the potential value of selectively targeting the BD2 domain of BET family proteins for cancer therapy.

2138861-99-9
DC11887 Alobresib

Alobresib is a novel BET bromodomain inhibitor with antineoplastic activity..

1637771-14-2
DC10334 ARV-771

ARV-771 is a potent bromodomain and extra-terminal (BET) proteins degrader with Kd values of 4.7, 7.6, 7.6 nM against bromodomain 2, 3 and 4, respectively.

1949837-12-0
DC12024 ARV-825

ARV-825 is a BRD4 Inhibitor based on PROTAC technology. ARV-825 binds to BD1 and BD2 of BRD4 with Kds of 90 and 28 nM, respectively.

1818885-28-7
DC10288 AZD5153 6-Hydroxy-2-naphthoic acid

AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC50 of 1.7 nM.

1869912-40-2
DC10774 AZD5153

AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor.

1869912-39-9
DC12029 BAY-299

BAY-299 is a potent and selective inhibitor of the bromodomain and PHD finger-containing (BRPF) family protein BRD1 (IC50 = 6 nM).

2080306-23-4
DC11505 BAY-850

BAY-850 (BAY 850, BAY850) is a potent, isoform selective, cellularly active ATAD2 bromodomain inhibitor with binding IC50 of 166 nM in TR-FRET assay.

2099142-76-2
DC7854 BAZ2-ICR

BAZ2-ICR is a selective BAZ2 bromodomain inhibitor (Kd values are 109 and 170 nM for BAZ2A and BAZ2B respectively).

1665195-94-7
DC11042 BET inhibitor CF53

BET inhibitor CF53 is a highly potent, orally active inhibitor of bromodomain and extra-terminal (BET) with Ki of <1 nM (BRD4 BD1).

1808160-52-2
DC8556 BET-BAY 002

BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.

1588521-78-1
DC9724 BI-7273

BI-7273 is a potent, selective, and cell-permeable BRD9 BD Inhibitor.

1883429-21-9
Page 1 / Total 3 FirstPrevNextLastGoto